Parkman Healthcare Partners’s Acceleron Pharma XLRN Stock Holding History

Parkman Healthcare Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-60,074	Closed	-$7.54M	–	91
2021 Q2	$7.54M	Sell	60,074 -2,706	-4%	-$341K	1.65%	18
2021 Q1	$8.51M	Buy	62,780 +10,322	+20%	+$1.33M	1.98%	15
2020 Q4	$6.71M	Buy	52,458 +2,442	+5%	+$286K	1.72%	23
2020 Q3	$5.63M	Sell	50,016 -7,484	-13%	-$745K	1.49%	26
2020 Q2	$5.48M	Buy	57,500 +20,000	+53%	+$1.93M	1.54%	28
2020 Q1	$3.37M	Buy	+37,500	New	+$2.91M	1.56%	24

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Parkman Healthcare Partners's XLRN Position: Q3 2021 in Review

Parkman Healthcare Partners sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 60,074 shares — an estimated $7.54M sold.

Parkman Healthcare Partners first reported a position in XLRN in Q1 2020 and held it in 6 quarters. The position peaked at $8.51M in Q1 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Parkman Healthcare Partners reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Parkman Healthcare Partners sold 60,074 Acceleron Pharma shares in Q3 2021, an estimated $7.54M.
Parkman Healthcare Partners first reported a position in Acceleron Pharma in Q1 2020 and held it in 6 quarters.
Parkman Healthcare Partners's Acceleron Pharma position peaked at $8.51M in Q1 2021.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Parkman Healthcare Partners's 13F filing for Q3 2021, filed 12 Nov 2021.